Theravance (THRX) Higher After Compound Shows Clinical Significance
More News related to GSK
- Swine Flu Cases Decline to Lowest Level in 2+ Months
- Severe Reactions Spur GlaxoSmithKline to Pull Batch of H1N1 Swine Flu Vaccine in Canada, an Industrial Info News Alert
- Most Surveyed Clinicians Will Prescribe Amgen/GlaxoSmithKline's Prolia as Either a Second- or Third-Line Therapy for Osteoporosis
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
More News related to THRX
- Theravance to Present at the Deutsche Bank 2009 Biotech Boston Confab
- Theravance Announces New Employment Inducement Awards
- Theravance (THRX) MAA for Telavarion Validated by EMEA
- Theravance Announces That EMEA Has Completed the Validation Phase for the Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections
- Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
More News related to FDA
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
Theravance, Inc. (Nasdaq: THRX) is 13% higher in after-hours trading after the company announced the results of two studies in an ongoing Phase 2b clinical program to assess the efficacy and safety of the investigational bronchodilators GSK642444 ('444) and GSK159797 ('797), the lead long-acting Beta2 agonist compounds in the Beyond Advair collaboration with GlaxoSmithKline (NYSE: GSK).
In the studies, '444, a GSK-discovered compound, and '797, a Theravance-discovered compound, each given once daily, achieved clinically significant increases in bronchodilation at least equivalent to salmeterol given twice daily. Both compounds exhibited a pharmacodynamic profile similar to other inhaled LABAs, with little impact on heart rate.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.31Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
